In the last 20 years, monoclonal antibody–based treatment for cancer has proven one of the most effective therapeutic strategies for solid tumors, as well as tumors of hematopoietic and lymphoid tissues. Therapeutic antibodies against cancer are used and designed to target cancer surface antigens or to unlock checkpoint inhibitors.
Therapeutic antibody research usually starts with identification and validation of targets for immunotherapy. For subsequent discovery of antibody candidates, B cells are used either for sequencing of B cell receptors (BCRs) or B cell cultivation and binder selection. The final step, antibody functionality is verified using cell-based assays to determine the mode of action and effector function. Often, additional optimization of antibody candidates and further functionality testing is performed to improve specificity, safety, and efficacy.
Our goal is it to support you at every step of your workflow, to simplify your research, and ensure reproducibility in your data.
Seems like you are coming from USA!
Do you want to visit our website in your country?